The direct receipts support a narrow working claim: RT reduced 93.5% of CR-induced LBM loss; change in strength/LBM ratio tended to be different (p = 0.07) following CRRT (20.9 ± 23.1%) and CR (−7.5 ± 9.9%). The context receipts provide source breadth and boundary checks, not independent confirmation of the lead claim.

sha256:e3f90e3768ad811fec9d22947b2c7e1b11bbe799a5bb1e186facda3e350707ce

## One-sentence thesis

The direct receipts support a narrow working claim: RT reduced 93.5% of CR-induced LBM loss; change in strength/LBM ratio tended to be different (p = 0.07) following CRRT (20.9 ± 23.1%) and CR (−7.5 ± 9.9%). The context receipts provide source breadth and boundary checks, not independent confirmation of the lead claim.

**Interpretation note:** This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication.

## Why this is surprising

Real tension: the useful signal is narrower than the topic label. The lead receipts support the core claim, while the added A/B context receipts define where that claim may generalize, fail, or need a separate extraction.

## Evidence receipts

- `fact_id=100758` (`A_core`) — RT reduced 93.5% of CR-induced LBM loss doi=10.3390/nu10040423
- `fact_id=100761` (`A_core`) — change in strength/LBM ratio tended to be different (p = 0.07) following CRRT (20.9 ± 23.1%) and CR (−7.5 ± 9.9%) doi=10.3390/nu10040423
- `fact_id=183811` (`A_core`) — when TRF is combined with caloric restriction, weight loss is >5% of the initial body weight doi=10.3390/nu14224778
- `fact_id=185351` (`A_core`) — Studies with subtherapeutic dosing typically used more moderate caloric restrictions (reducing energy intake by 500-600 kcal/day) and the weighted mean remission rate was 6.9% doi=10.1177/1559827620930962
- `fact_id=161504` (`A_core`) — 30% CR was sufficient to extend the life span by 10% doi=10.1126/science.abk0297
- `fact_id=162990` (`A_core`) — 30% CR in young male mice decreased fat mass and improved glucose tolerance and insulin sensitivity doi=10.7554/elife.88080

## Context receipts

_Boundary evidence only; these receipts broaden source context but do not independently prove the lead claim._

- `fact_id=100759` (`B_context`) — 0.819 kg [0.364 to 1.273] of CR-induced LBM loss prevented doi=10.3390/nu10040423
- `fact_id=173560` (`B_context`) — a 7-day water-only fast leads to an average weight loss of 5.7 kg (±0.8 kg) among 12 volunteers doi=10.1038/s42255-024-01008-9
- `fact_id=141623` (`B_context`) — 40% caloric restriction had the strongest lifespan extension effect. doi=10.1038/s41586-024-08026-3

## What this changes

Treat this as a focused working signal, not a broad topic claim. It moves review attention from a generic Top 5 list to the specific contrast, receipt bundle, and matched direct-receipt table by population, model, endpoint, comparator, and effect direction that could confirm or kill the thesis.

## Limitations

- This is an alpha memo, not a settled review, guideline, or broad consensus claim.
- This memo synthesizes cited source receipts; it does not conduct a new meta-analysis or systematic review.
- Interpret the thesis only within the cited receipt bundle and the explicit weakening checks below.
- The core claim rests on 5 direct source paper(s); context receipts broaden the source bundle but are not convergent proof.
- Independent receipts fail to reproduce the claimed contrast.
- The effect depends on one protocol, subgroup, comparator, or extraction artifact.

## What would weaken this

- Independent receipts fail to reproduce the claimed contrast.
- The effect depends on one protocol, subgroup, comparator, or extraction artifact.

## Strongest counter-evidence

- `fact_id=146839` (`A_core`) — n = 220 adults without obesity were randomized to 25% CR or ad libitum control diet for 2 yr Source: Effect of long-term caloric restriction on DNA methylation measures of biological aging in healthy adults from the CALERIE trial

## Next extraction

- Extract independent A_core/B_context receipts that test the lead contrast directly.
- Audit whether each direct receipt remains comparable on population, endpoint, comparator, and measurement method.
- Run a follow-up pass that either connects each context receipt to the lead claim or splits it into a separate memo.


Resistance training as a countermeasure to caloric restriction-induced lean mass loss: evidence from obese elderly and heart failure patients

The cited A/B receipts support a specific working claim: rapamycin led to a 217% and 106% increase of M1 (CD45+CD64+CD206−) ATMs in females; rapamycin led to a 217% and 106% increase of M1 (CD45+CD64+CD206−) ATMs in females and males, respectively. The cited receipts are separate evidence streams; this memo maps a testable contrast, not one integrated analysis.

sha256:eaacf93a88c861870ece2f4f18a813b0d401a6c26dbc5ce7d748184278d1f9f3

## One-sentence thesis

The cited A/B receipts support a specific working claim: rapamycin led to a 217% and 106% increase of M1 (CD45+CD64+CD206−) ATMs in females; rapamycin led to a 217% and 106% increase of M1 (CD45+CD64+CD206−) ATMs in females and males, respectively. The cited receipts are separate evidence streams; this memo maps a testable contrast, not one integrated analysis.

**Interpretation note:** This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication.

## Why this is surprising

Rapamycin's anti-aging efficacy is entangled with sex-specific pro-inflammatory remodeling of adipose tissue macrophages, creating a paradox where immune activation may both undermine and enhance longevity depending on context. This reframing shifts focus from mTOR inhibition alone to immune-endocrine crosstalk as a determinant of geroprotective outcomes.

Known / obvious (do not republish): Rapamycin extends median lifespan in C57BL/6 mice by 60% with transient treatment; Rapamycin at 42 ppm extends median lifespan by 23-26% in UM-HET3 mice; Rapamycin is an mTOR inhibitor used in transplantation for immunosuppression

Real tension: Transient high-dose rapamycin (8 mg/kg/day i.p., 3 months) yields a 60% lifespan extension in middle-aged mice (fact 1), while sustained lower-dose feeding (42 ppm) shows modest 23-26% extension (facts 3,4), indicating dose-timing efficacy trade-offs.

## Evidence receipts

- `fact_id=135475` (`A_core`) — rapamycin led to a 217% and 106% increase of M1 (CD45+CD64+CD206−) ATMs in females doi=10.1093/gerona/glz177
- `fact_id=135476` (`A_core`) — rapamycin led to a 217% and 106% increase of M1 (CD45+CD64+CD206−) ATMs in females and males, respectively doi=10.1093/gerona/glz177
- `fact_id=135477` (`A_core`) — rapamycin led to a 56% increase of CD45+ leukocytes in gWAT, where the majority of these are ATMs doi=10.1093/gerona/glz177
- `fact_id=rapamycin/transient/bitto_2016/lifespan_extension` (`A_core`) — 3 months of rapamycin extended remaining lifespan by ~60% in middle-aged mice doi=10.7554/eLife.16351
- `fact_id=rapamycin/itp/harrison_2009/lifespan_female` (`A_core`) — rapamycin reduced 90th-percentile mortality by 14% in females (Harrison 2009 NIA-ITP, 14 ppm) doi=10.1038/nature08221
- `fact_id=rapamycin/itp/miller_2014/dose_response_high_male` (`A_core`) — rapamycin at 42 ppm extended male median lifespan by 23% doi=10.1111/acel.12194
- `fact_id=166319` (`A_core`) — Metformin (0.1%) combined with rapamycin (14 ppm) robustly extended lifespan, suggestive of an added benefit. doi=10.1111/acel.12496

## What this changes

Treat this as a focused working signal, not a broad topic claim. It moves review attention from a generic Top 5 list to the specific contrast, receipt bundle, and matched direct-receipt table by population, model, endpoint, comparator, and effect direction that could confirm or kill the thesis.

## Limitations

- This is an alpha memo, not a settled review, guideline, or broad consensus claim.
- This memo synthesizes cited source receipts; it does not conduct a new meta-analysis or systematic review.
- Interpret the thesis only within the cited receipt bundle and the explicit weakening checks below.
- Independent receipts fail to reproduce the claimed contrast.
- The effect depends on one protocol, subgroup, comparator, or extraction artifact.

## What would weaken this

- Independent receipts fail to reproduce the claimed contrast.
- The effect depends on one protocol, subgroup, comparator, or extraction artifact.

## Strongest counter-evidence

- _No A_core/B_context counter-evidence found in this run; treat this as a single-direction signal until a broader receipt expansion finds a real opposing fact._

## Next extraction

- Extract independent A_core/B_context receipts that test the lead contrast directly.
- Audit whether each direct receipt remains comparable on population, endpoint, comparator, and measurement method.


Sex-specific adipose tissue macrophage activation as a predictive biomarker for rapamycin's lifespan outcomes

sha256:e2e42f92e440135444f23480eb7be4eaaeff880cf53bb5445837286fe8f1e848

# Alpha memo — metformin

**Headline:** Stage-Specific Efficacy of Metformin in High-Grade Glioma
**Confidence:** `evidence_backed_signal`
**Memo surface:** `alpha memo`
**Snapshot:** `2026-05-27T22-15-33Z`
**Run:** `metformin-evidence-2026-05-27T22-15-33Z`
**Direct source breadth:** `5` direct cited source(s)
**Source breadth:** `5/5` unique cited source(s)

## One-sentence thesis

The cited A/B receipts support a specific working claim: Use of metformin was associated with a significantly better overall and progression-free survival of patients with WHO grade III glioma (HR for OS = 0.30; 95% CI = 0.11-0.81); HR for PFS = 0.29; 95% CI = 0.11-0.78. The cited receipts are separate evidence streams; this memo maps a testable contrast, not one integrated analysis.

**Scope clarification:** The lead claim should be read as a narrow direct-source signal. Other cited sources provide context and boundary checks, not independent confirmation of the lead claim.

**Interpretation note:** This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication.

## Why this is surprising

Metformin's clinical effects are stratified by disease pathology and acuity, as shown by its selective survival benefit in WHO grade III but not grade IV glioma and its consistent mortality reduction in acute sepsis and COVID-19, suggesting context-dependent mechanisms that challenge uniform therapeutic application.

Known / obvious (do not republish): Metformin is a first-line therapy for glycemic control in type 2 diabetes.; General association between metformin use and reduced cancer incidence in diabetic populations.

Real tension: Divergent survival outcomes in metformin-treated patients: significant HR for OS and PFS in WHO grade III glioma versus non-significant HR in grade IV glioma (facts 80429, 80430 vs 80432, 80431).

## Evidence receipts

- `fact_id=80429` (`A_core`) — Use of metformin was associated with a significantly better overall and progression-free survival of patients with WHO grade III glioma (HR for OS = 0.30; 95% CI = 0.11-0.81) doi=10.1002/ijc.31783
- `fact_id=80430` (`A_core`) — HR for PFS = 0.29; 95% CI = 0.11-0.78 doi=10.1002/ijc.31783
- `fact_id=80432` (`A_core`) — there were no significant relations with PFS (HR = 0.85; 95% CI = 0.59-1.22) in patients with WHO grade IV glioma doi=10.1002/ijc.31783
- `fact_id=80431` (`A_core`) — there were no significant relations with OS (HR = 0.83; 95% CI = 0.57-1.20) in patients with WHO grade IV glioma doi=10.1002/ijc.31783
- `fact_id=187131` (`A_core`) — adjusted hazard ratio of 0.34 (95% confidence interval: 0.33 to 0.36) doi=10.1093/brain/awad366
- `fact_id=165590` (`A_core`) — preadmission metformin use was associated with 39% lower of 30-day mortality (HR = 0.61, 95% CI: 0.46-0.81, p = 0.007) doi=10.3389/fmed.2021.640785
- `fact_id=183308` (`A_core`) — a combined Odds Ratio of 0.468; 95% CI 0.275-0.799 for the association between HCC and the use of metformin. doi=10.1016/j.aohep.2019.10.005
- `fact_id=186225` (`A_core`) — metformin is associated with 34% lower COVID-19 mortality [odds ratio (OR), 0.66; 95% confidence interval (CI), 0.56-0.78] doi=10.3389/fmed.2021.704666

## What this changes

Treat this as a focused working signal, not a broad topic claim. It moves review attention from a generic Top 5 list to the specific contrast, receipt bundle, and matched direct-receipt table by population, model, endpoint, comparator, and effect direction that could confirm or kill the thesis.

## Limitations

- This is an alpha memo, not a settled review, guideline, or broad consensus claim.
- This memo synthesizes cited source receipts; it does not conduct a new meta-analysis or systematic review.
- Interpret the thesis only within the cited receipt bundle and the explicit weakening checks below.
- Independent receipts fail to reproduce the claimed contrast.
- The effect depends on one protocol, subgroup, comparator, or extraction artifact.

## What would weaken this

- Independent receipts fail to reproduce the claimed contrast.
- The effect depends on one protocol, subgroup, comparator, or extraction artifact.

## Strongest counter-evidence

- _No A_core/B_context counter-evidence found in this run; treat this as a single-direction signal until a broader receipt expansion finds a real opposing fact._

## Next extraction

- Extract independent A_core/B_context receipts that test the lead contrast directly.
- Audit whether each direct receipt remains comparable on population, endpoint, comparator, and measurement method.

## Provenance / priority

- **Topic:** `metformin`
- **Author:** Dom Lynch
- **ORCID:** _not configured_
- **Version:** 1.0
- **License:** CC BY-NC 4.0
- **Canonical URL:** _not assigned_
- **Suggested citation:** Dom Lynch. (2026). Stage-Specific Efficacy of Metformin in High-Grade Glioma. ReseaRka Evidence Index. Version 1.0.
- **Run bundle SHA-256:** `0ca3b0dbd4c78e7e8f59d69181e50297c481b66b96c05eb210c9b366d5b68370`
- **Memo SHA-256:** `10e52e4e143d6d5e733be1f1baa75151920b11e15ab996ba998300a72c3316c3`
- **Priority note:** This memo records the first published framing, source bundle, and evidence receipts for this run. Reuse should cite the canonical version.


Stage-Specific Efficacy of Metformin in High-Grade Glioma

sha256:6a30e0296b0742690e712fec2a1767acf70963de0db0cc7ce7ed2f4bae35abf9

# Alpha memo — telomere

**Headline:** Cardiovascular protection versus cancer risk: a Mendelian randomization and meta-analysis synthesis of telomere length effects
**Confidence:** `evidence_backed_signal`
**Memo surface:** `alpha memo`
**Snapshot:** `2026-05-27T19-41-35Z`
**Run:** `telomere-evidence-2026-05-27T19-41-35Z`
**Direct source breadth:** `5` direct cited source(s)
**Source breadth:** `5/5` unique cited source(s)

## One-sentence thesis

The cited A/B receipts support a specific working claim: Genetically determined longer telomere length was associated with lowered risk of coronary heart disease (CHD; OR = 0.95, 95% CI: 0.92-0.98); but raised risk of cancer (OR = 1.11, 95% CI: 1.06-1.16). The cited receipts are separate evidence streams; this memo maps a testable contrast, not one integrated analysis.

**Interpretation note:** This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication.

## Why this is surprising

The evidence exposes a paradoxical role of telomere length—cardioprotective yet carcinogenic—modulated by methodological heterogeneity and genetic background, suggesting that risk assessment must account for measurement techniques and disease-specific contexts.

Known / obvious (do not republish): Telomere length shortens with chronological age; Shorter telomeres are associated with increased all-cause mortality risk

Real tension: Fact 109012 (lower CHD risk with longer TL) vs Fact 109013 (higher cancer risk with longer TL) in the same UK Biobank population aged 60+

## Evidence receipts

- `fact_id=109012` (`A_core`) — Genetically determined longer telomere length was associated with lowered risk of coronary heart disease (CHD; OR = 0.95, 95% CI: 0.92-0.98) doi=10.1111/acel.13017
- `fact_id=109013` (`A_core`) — but raised risk of cancer (OR = 1.11, 95% CI: 1.06-1.16) doi=10.1111/acel.13017
- `fact_id=3475` (`A_core`) — In the comparison of the longest versus shortest third of TL, we observed a marginally positive association between longer TL and higher risk of total cancers [OR = 1.086; 95% CI, 0.952-1.238]. doi=10.1158/1055-9965.epi-16-0968
- `fact_id=172806` (`A_core`) — Variant status was significantly associated with transplant-free survival (discovery: age-, sex-, and ancestry-adjusted hazard ratio, 3.73) doi=10.1164/rccm.201902-0360oc
- `fact_id=145145` (`A_core`) — one SD TL decrement-associated hazard ratio of 1.09 (95% CI: 1.06-1.13) doi=10.1016/j.arr.2018.09.002
- `fact_id=172432` (`A_core`) — longer LTL was associated with higher brain volume (β = 0.43, 95%CI: 0.36-0.50%, p = 0.008, N = 1102) doi=10.1016/j.arr.2022.101679

## What this changes

Treat this as a focused working signal, not a broad topic claim. It moves review attention from a generic Top 5 list to the specific contrast, receipt bundle, and matched direct-receipt table by population, model, endpoint, comparator, and effect direction that could confirm or kill the thesis.

## Limitations

- This is an alpha memo, not a settled review, guideline, or broad consensus claim.
- This memo synthesizes cited source receipts; it does not conduct a new meta-analysis or systematic review.
- Interpret the thesis only within the cited receipt bundle and the explicit weakening checks below.
- Independent receipts fail to reproduce the claimed contrast.
- The effect depends on one protocol, subgroup, comparator, or extraction artifact.

## What would weaken this

- Independent receipts fail to reproduce the claimed contrast.
- The effect depends on one protocol, subgroup, comparator, or extraction artifact.

## Strongest counter-evidence

- _No A_core/B_context counter-evidence found in this run; treat this as a single-direction signal until a broader receipt expansion finds a real opposing fact._

## Next extraction

- Extract independent A_core/B_context receipts that test the lead contrast directly.
- Audit whether each direct receipt remains comparable on population, endpoint, comparator, and measurement method.

## Provenance / priority

- **Topic:** `telomere`
- **Author:** Dom Lynch
- **ORCID:** _not configured_
- **Version:** 1.0
- **License:** CC BY-NC 4.0
- **Canonical URL:** _not assigned_
- **Suggested citation:** Dom Lynch. (2026). Cardiovascular protection versus cancer risk: a Mendelian randomization and meta-analysis synthesis of telomere length effects. ReseaRka Evidence Index. Version 1.0.
- **Run bundle SHA-256:** `f87d32bf6f8024c7c1786fe09d30916f479b7ad4aca236ffc5ac42b88539b95c`
- **Memo SHA-256:** `f1f71321d545b30354457fc320f7134991a8f498ff2c6db93ce7f3bed6b1e00e`
- **Priority note:** This memo records the first published framing, source bundle, and evidence receipts for this run. Reuse should cite the canonical version.


Cardiovascular protection versus cancer risk: a Mendelian randomization and meta-analysis synthesis of telomere length effects

sha256:d170178dd79ad64f15a13656001f91f83d808905b635976093b90414311945fe

# Alpha memo — acarbose

**Headline:** Polypharmacy Strategies with Acarbose for Dementia Risk Reduction in Type 2 Diabetes: Evidence from Subgroup Analyses and Combination Therapy
**Confidence:** `evidence_backed_signal`
**Memo surface:** `alpha memo`
**Snapshot:** `2026-05-27T09-58-52Z`
**Run:** `acarbose-evidence-2026-05-27T09-58-52Z`
**Direct source breadth:** `5` direct cited source(s)
**Source breadth:** `5/5` unique cited source(s)

## One-sentence thesis

The cited A/B receipts support a specific working claim: reduced risk associated with acarbose was only observed... in non-users of metformin (adjusted hazard ratio, 0.635; 95% confidence interval, 0.481-0.837); users of all three drugs had the lowest risk of dementia (hazard ratio, 0.406; 95% confidence interval, 0.178-0.925). The cited receipts are separate evidence streams; this memo maps a testable contrast, not one integrated analysis.

**Interpretation note:** This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication.

## Why this is surprising

The discordance between acarbose's pronounced male-specific lifespan extension in genetically heterogeneous mice and its female-preferential dementia risk reduction in human type 2 diabetes patients suggests that sex-hormone interactions or differential gut-brain axis modulation may underpin its geroprotective effects, inviting mechanistic studies beyond glucose lowering.

Known / obvious (do not republish): Acarbose is an alpha-glucosidase inhibitor used to lower postprandial blood glucose in type 2 diabetes.; Acarbose improves glycemic control by delaying carbohydrate absorption in the intestine.

Real tension: Acarbose increased median lifespan by 22% in male mice but only 5% in female mice (facts 3,4), whereas in human T2D patients, it reduced dementia risk only in women with an HR of 0.783 (fact 12).

## Evidence receipts

- `fact_id=187300` (`A_core`) — reduced risk associated with acarbose was only observed... in non-users of metformin (adjusted hazard ratio, 0.635; 95% confidence interval, 0.481-0.837) doi=10.14336/ad.2019.0621
- `fact_id=187299` (`A_core`) — users of all three drugs had the lowest risk of dementia (hazard ratio, 0.406; 95% confidence interval, 0.178-0.925) doi=10.14336/ad.2019.0621
- `fact_id=187298` (`A_core`) — 0.918 (0.845-0.998) for every 1-year increment of cumulative duration of acarbose therapy doi=10.14336/ad.2019.0621
- `fact_id=135514` (`A_core`) — The mean HbA1c at week 24 was significantly decreased approximately 0.7% from baseline in both acarbose and voglibose groups. doi=10.3346/jkms.2014.29.1.90
- `fact_id=70369` (`A_core`) — Acarbose increased male median lifespan by 22% (P < 0.0001) doi=10.1111/acel.12170
- `fact_id=135510` (`A_core`) — acarbose produced 51% decrease in maltose loaded diabetic rats doi=10.4236/jdm.2012.21013
- `fact_id=108410` (`A_core`) — significantly increased (3%) in females only at 1,000 ppm doi=10.1111/acel.12898

## What this changes

Treat this as a focused working signal, not a broad topic claim. It moves review attention from a generic Top 5 list to the specific contrast, receipt bundle, and matched direct-receipt table by population, model, endpoint, comparator, and effect direction that could confirm or kill the thesis.

## Limitations

- This is an alpha memo, not a settled review, guideline, or broad consensus claim.
- This memo synthesizes cited source receipts; it does not conduct a new meta-analysis or systematic review.
- Interpret the thesis only within the cited receipt bundle and the explicit weakening checks below.
- Independent receipts fail to reproduce the claimed contrast.
- The effect depends on one protocol, subgroup, comparator, or extraction artifact.

## What would weaken this

- Independent receipts fail to reproduce the claimed contrast.
- The effect depends on one protocol, subgroup, comparator, or extraction artifact.

## Strongest counter-evidence

- _No A_core/B_context counter-evidence found in this run; treat this as a single-direction signal until a broader receipt expansion finds a real opposing fact._

## Next extraction

- Extract independent A_core/B_context receipts that test the lead contrast directly.
- Audit whether each direct receipt remains comparable on population, endpoint, comparator, and measurement method.

## Provenance / priority

- **Topic:** `acarbose`
- **Author:** Dom Lynch
- **ORCID:** _not configured_
- **Version:** 1.0
- **License:** CC BY-NC 4.0
- **Canonical URL:** _not assigned_
- **Suggested citation:** Dom Lynch. (2026). Polypharmacy Strategies with Acarbose for Dementia Risk Reduction in Type 2 Diabetes: Evidence from Subgroup Analyses and Combination Therapy. ReseaRka Evidence Index. Version 1.0.
- **Run bundle SHA-256:** `3d52b42b2eef9077a0c62041abf8adb8d43ceebe45f152cf94dee9baec1ad512`
- **Memo SHA-256:** `91120f14f4fab94a9d4c0b507c6b9d9cbc242e9a9636797539d71156d94b7ffc`
- **Priority note:** This memo records the first published framing, source bundle, and evidence receipts for this run. Reuse should cite the canonical version.


Polypharmacy Strategies with Acarbose for Dementia Risk Reduction in Type 2 Diabetes: Evidence from Subgroup Analyses and Combination Therapy

sha256:e73dcf03405a9629fbf28484081b12efa9de86d23326637941879a032f3d0ac7

# Alpha memo — exercise

**Headline:** Exercise: single-source lead signal with broader context receipts
**Alpha triage:** `high` (internal ranking; not a certainty claim)
**Confidence:** `evidence_backed_signal`
**Memo surface:** `alpha memo`
**Snapshot:** `2026-05-16T18-12-38Z`
**Run:** `exercise-evidence-2026-05-16T18-12-38Z`
**Direct source breadth:** `1` direct cited source(s)
**Source thesis:** Pathway-specific anti-inflammatory gating: metformin unlocks TNF-axis suppression in exercise-responsive cancer survivors that exercise alone cannot achieve
**Source breadth:** `5/5` unique cited source(s)

## One-sentence thesis

The direct receipts support a narrow working claim: Compared with control, exercise alone reduced hs-CRP [-30.2%; 95% CI, -50.3, -1.0]; exercise alone reduced hs-CRP and IL6 (-30.9%; 95% CI, -47.3, -9.5). The context receipts provide source breadth and boundary checks, not independent confirmation of the lead claim.

## Why this is surprising

The useful signal is narrower than the topic label: the lead receipts support the core claim, while the added A/B context receipts define where that claim may generalize, fail, or need a separate extraction.

## Evidence receipts

- `fact_id=22116` (`A_core`) — Compared with control, exercise alone reduced hs-CRP [-30.2%; 95% CI, -50.3, -1.0] DOI `10.1158/1940-6207.capr-20-0188`
- `fact_id=22117` (`A_core`) — exercise alone reduced hs-CRP and IL6 (-30.9%; 95% CI, -47.3, -9.5) DOI `10.1158/1940-6207.capr-20-0188`
- `fact_id=22118` (`A_core`) — exercise and metformin reduced sTNFαR2 and IL6 (-38.7%; 95% CI, -52.3, -18.9) DOI `10.1158/1940-6207.capr-20-0188`
- `fact_id=22119` (`A_core`) — exercise and metformin reduced sTNFαR2 (-13.1%; 95% CI, -22.9, -1.0) DOI `10.1158/1940-6207.capr-20-0188`

## Context receipts

- `fact_id=12572` (`A_core`) — Mixed-muscle protein fractional synthetic rate increased by 42% at 3 h postexercise and 69% at 24 h postexercise in CON. DOI `10.1152/ajpendo.00600.2013`
- `fact_id=41245` (`A_core`) — tumor-bearing mice with access to running wheels showed reduced growth of MDA-MB-231 (-66%, P < 0.01) tumors DOI `10.1158/0008-5472.can-16-3125`
- `fact_id=12544` (`A_core`) — Mortality risk was 11% lower (hazard ratio, 0.89; 95% confidence interval, 0.86-0.93; P<0.001) for every 1-MET increase in exercise capacity. DOI `10.1161/hypertensionaha.114.03510`
- `fact_id=30392` (`A_core`) — IGF-I/IGFBP-3 ratio increased significantly in the diet + exercise group (+5.4%, P < 0.01) compared with control. DOI `10.1158/1055-9965.epi-13-0337`

## What this changes

Treat this as a focused working signal, not a broad topic claim. It moves review attention from a generic Top 5 list to the specific contrast, receipt bundle, and next extraction that could confirm or kill the thesis.

## Limitations

- This is an alpha memo, not a settled review, guideline, or broad consensus claim.
- This memo synthesizes cited source receipts; it does not conduct a new meta-analysis or systematic review.
- Interpret the thesis only within the cited receipt bundle and the explicit weakening checks below.
- The core claim rests on 1 direct source paper(s); context receipts broaden the source bundle but are not convergent proof.
- Independent receipts fail to reproduce the claimed contrast.
- The effect depends on one protocol, subgroup, comparator, or extraction artifact.

## What would weaken this

- Independent receipts fail to reproduce the claimed contrast.
- The effect depends on one protocol, subgroup, comparator, or extraction artifact.

## Strongest counter-evidence

- _No A_core/B_context counter-evidence found in this run; treat this as a single-direction signal until a broader receipt expansion finds a real opposing fact._

## Next extraction

- Extract independent A_core/B_context receipts that test the lead contrast directly.
- Audit whether each direct receipt remains comparable on population, endpoint, comparator, and measurement method.
- Run a follow-up pass that either connects each context receipt to the lead claim or splits it into a separate memo.

## Provenance / priority

- **Topic:** `exercise`
- **Author:** Dom Lynch
- **ORCID:** _not configured_
- **Version:** 1.0
- **License:** CC BY-NC 4.0
- **Canonical URL:** _not assigned_
- **Suggested citation:** Dom Lynch. (2026). Exercise: single-source lead signal with broader context receipts. ReseaRka Evidence Index. Version 1.0.
- **Run bundle SHA-256:** `fe487b28cd8297287f8c8def5605a5aac25b0a1723c07436f22dfdaea7dc6374`
- **Memo SHA-256:** `12c36db3312628e59f58153f26a3a4e818cb983d57e130624eff79bc4b43b487`
- **Priority note:** This memo records the first published framing, source bundle, and evidence receipts for this run. Reuse should cite the canonical version.


Exercise: single-source lead signal with broader context receipts

sha256:dcf760e2c26b102d143e2f21a32e066088c2a2358babfa644b456ee053aa96fa

# Alpha memo — telomere

**Headline:** The Telomere Length Paradox: Quantifying Trade-offs Between Cardioprotection and Carcinogenesis Across Subgroups
**Alpha score:** 100/100 (internal triage score; not a certainty claim)
**Confidence:** `evidence_backed_signal`
**Memo surface:** `alpha memo`
**Snapshot:** `2026-05-24T14-42-28Z`
**Run:** `telomere-evidence-2026-05-24T14-42-28Z`

## One-sentence thesis

The Telomere Length Paradox: Quantifying Trade-offs Between Cardioprotection and Carcinogenesis Across Subgroups

## Why this is surprising

Telomere length emerges as a dualistic biomarker where elongation simultaneously lowers cardiovascular risk but elevates cancer susceptibility, with the magnitude of these effects critically modulated by genetic variants, measurement precision, and disease-specific contexts like pulmonary fibrosis.

Known / obvious (do not republish): Telomere length shortens with age; Shorter telomeres are generally associated with higher mortality risk; Telomere length is influenced by genetic factors

Real tension: Fact 1 shows genetically determined longer telomere length lowers coronary heart disease risk, while facts 4 and 7 indicate it raises cancer risk, creating a therapeutic dilemma.

## Evidence receipts

- `fact_id=109012` (`A_core`) — Genetically determined longer telomere length was associated with lowered risk of coronary heart disease (CHD; OR = 0.95, 95% CI: 0.92-0.98) DOI `10.1111/acel.13017`
- `fact_id=109013` (`A_core`) — but raised risk of cancer (OR = 1.11, 95% CI: 1.06-1.16) DOI `10.1111/acel.13017`
- `fact_id=3476` (`A_core`) — the association was stronger in lung cancer (n = 3; OR = 1.690; 95% CI, 1.253-2.280) DOI `10.1158/1055-9965.epi-16-0968`
- `fact_id=3477` (`A_core`) — in men (n = 6; OR = 1.302; 95% CI, 1.120-1.514) DOI `10.1158/1055-9965.epi-16-0968`

## What this changes

Treat this as a focused working signal, not a broad topic claim. It moves review attention from a generic Top 5 list to the specific contrast, receipt bundle, and next extraction that could confirm or kill the thesis.

## Limitations

- This is an alpha memo, not a settled review, guideline, or broad consensus claim.
- Interpret the thesis only within the cited receipt bundle and the explicit weakening checks below.
- Confounding by unmeasured genetic or lifestyle factors in observational studies linking telomere length to disease outcomes.
- Small subgroup sample sizes (e.g., lung cancer, n=3 in fact 11) limit statistical power and generalizability.
- Potential publication bias favoring positive associations in telomere-length studies, especially in meta-analyses.

## What would weaken this

- Confounding by unmeasured genetic or lifestyle factors in observational studies linking telomere length to disease outcomes.
- Small subgroup sample sizes (e.g., lung cancer, n=3 in fact 11) limit statistical power and generalizability.
- Potential publication bias favoring positive associations in telomere-length studies, especially in meta-analyses.

## Strongest counter-evidence

- _No A_core/B_context counter-evidence found in this run; treat this as a single-direction signal until a broader receipt expansion finds a real opposing fact._

## Next extraction

- Oxidative stress markers in relation to telomere dynamics across different populations
- Effects of specific viral infections (e.g., HIV, COVID-19) on telomere length in longitudinal cohorts
- Age-stratified analyses of telomere length associations with liver fibrosis or cognitive decline

## Supporting Top cards

- Variant status was significantly associated with transplant-free survival (discovery: age-, sex-, and ancestry-adjusted hazard ratio, 3.73) _(alpha cues: subgroup, translation_context, functional_endpoint)_
- one SD TL decrement-associated hazard ratio of 1.09 (95% CI: 1.06-1.13) _(alpha cues: functional_endpoint)_
- Genetically determined longer telomere length was associated with lowered risk of coronary heart disease (CHD; OR = 0.95, 95% CI: 0.92-0.98) _(alpha cues: translation_context)_
- the association was stronger in lung cancer (n = 3; OR = 1.690; 95% CI, 1.253-2.280) _(alpha cues: subgroup)_
- longer LTL was associated with higher brain volume (β = 0.43, 95%CI: 0.36-0.50%, p = 0.008, N = 1102) _(alpha cues: baseline)_

## Provenance / priority

- **Topic:** `telomere`
- **Author:** Dom Lynch
- **ORCID:** _not configured_
- **Version:** 1.0
- **License:** CC BY-NC 4.0
- **Canonical URL:** _not assigned_
- **Suggested citation:** Dom Lynch. (2026). The Telomere Length Paradox: Quantifying Trade-offs Between Cardioprotection and Carcinogenesis Across Subgroups. ReseaRka Evidence Index. Version 1.0.
- **Run bundle SHA-256:** `ab69949297858287f1eb29c51a9f98baccd34ca3e116719b882bfb0d39e58817`
- **Memo SHA-256:** `cd82be4cdbcd7d0e0656a9dc4e6c84208ead64361fdd1d70e0b93eeaa27ca430`
- **Priority note:** This memo records the first published framing, source bundle, and evidence receipts for this run. Reuse should cite the canonical version.


The Telomere Length Paradox: Quantifying Trade-offs Between Cardioprotection and Carcinogenesis Across Subgroups

A broad 12-reference exercise alpha memo distinguishing bound evidence from context references.

sha256:dc57e138d6cb05cd05ea9bcec40aa7d5c57cf42fb56dc237eb9060f46adc1a2b

# Alpha memo — exercise

**Headline:** Exercise signals are endpoint-specific, not uniformly generalizable
**Alpha score:** 100/100 (internal triage score; not a certainty claim)
**Confidence:** `evidence_backed_signal`
**Memo surface:** `broad alpha memo`
**Source scope:** 16 A/B-bound receipts across 10 evidence sources; 12 total references in the source bundle. Two source-bundle entries are corpus-context references for breadth, not thesis proof; schema labels still use primary/review only.

## One-sentence thesis

The exercise corpus in this run supports a broader alpha signal: exercise effects are endpoint- and context-specific rather than uniformly generalizable. The strongest bound receipts span inflammatory markers, exercise capacity and mortality, tumor-model response, angiogenesis biomarkers, muscle-protein synthesis, peripheral oxygen extraction, dietary inflammatory index, and NO/exercise muscle effects.

## Why this is surprising

The common story treats exercise as a single beneficial geroscience intervention. This evidence map says the more useful signal is specificity: different populations, endpoints, and mechanisms move differently, so the publishable claim is not “exercise works,” but “exercise signals need endpoint- and context-specific interpretation.”

## Evidence receipts

- `fact_id=12572` (`A_core`) — Mixed-muscle protein fractional synthetic rate increased by 42% at 3 h postexercise and 69% at 24 h postexercise in CON. DOI `10.1152/ajpendo.00600.2013`
- `fact_id=12573` (`A_core`) — Mixed-muscle protein fractional synthetic rate increased by 42% at 3 h postexercise and 69% at 24 h postexercise in CON. DOI `10.1152/ajpendo.00600.2013`
- `fact_id=41245` (`A_core`) — tumor-bearing mice with access to running wheels showed reduced growth of MDA-MB-231 (-66%, P < 0.01) tumors DOI `10.1158/0008-5472.can-16-3125`
- `fact_id=12544` (`A_core`) — Mortality risk was 11% lower (hazard ratio, 0.89; 95% confidence interval, 0.86-0.93; P<0.001) for every 1-MET increase in exercise capacity. DOI `10.1161/hypertensionaha.114.03510`
- `fact_id=22119` (`A_core`) — exercise and metformin reduced sTNFαR2 (-13.1%; 95% CI, -22.9, -1.0) DOI `10.1158/1940-6207.capr-20-0188`
- `fact_id=22117` (`A_core`) — exercise alone reduced hs-CRP and IL6 (-30.9%; 95% CI, -47.3, -9.5) DOI `10.1158/1940-6207.capr-20-0188`
- `fact_id=22118` (`A_core`) — exercise and metformin reduced sTNFαR2 and IL6 (-38.7%; 95% CI, -52.3, -18.9) DOI `10.1158/1940-6207.capr-20-0188`
- `fact_id=22116` (`A_core`) — Compared with control, exercise alone reduced hs-CRP [-30.2%; 95% CI, -50.3, -1.0] DOI `10.1158/1940-6207.capr-20-0188`
- `fact_id=30392` (`A_core`) — IGF-I/IGFBP-3 ratio increased significantly in the diet + exercise group (+5.4%, P < 0.01) compared with control. DOI `10.1158/1055-9965.epi-13-0337`
- `fact_id=15480` (`A_core`) — patients with PAD had a greater reduction in SmO2 (-54 ± 10 vs. -12 ± 4%, P = 0.001) DOI `10.1152/japplphysiol.01110.2016`
- `fact_id=29372` (`A_core`) — Participants randomized to the diet and diet + exercise arms had statistically significantly greater reductions in PEDF (-9.90%, P < 0.0001) compared with controls. DOI `10.1158/0008-5472.can-16-0399`
- `fact_id=29371` (`A_core`) — Participants randomized to the diet and diet + exercise arms had statistically significantly greater reductions in VEGF (-9.98%, P < 0.0001) compared with controls. DOI `10.1158/0008-5472.can-16-0399`
- `fact_id=29370` (`A_core`) — Participants randomized to the diet + exercise arms had statistically significantly greater reductions in PAI-1 at 12 months compared with controls (-19.3% vs. +3.48%, respectively, P < 0.0001). DOI `10.1158/0008-5472.can-16-0399`
- `fact_id=19252` (`A_core`) — protein synthetic response to exercise was blunted in obese rats: mixed -7%, myofibrillar +6%, cytosolic +7% vs. lean +34%, +40%, +17%. DOI `10.1096/fj.12-224006`
- `fact_id=27808` (`B_context`) — Participants randomized to diet and diet+exercise arms had greater reductions in E-DII (-104.4% and -84.4%), versus controls (-34.8%, both P < 0.001). DOI `10.1158/1940-6207.capr-20-0181`
- `fact_id=34200` (`A_core`) — NO-donor treatment with isosorbide dinitrate for 6 wk, in combination with voluntary exercise for 3 wk, increased muscle mass by 25% DOI `10.1152/ajpcell.00305.2011`

## Source bundle map

1. Activation of mTORC1 signaling and protein synthesis in human muscle following blood flow restriction exercise is inhibited by rapamycin (2014). DOI `10.1152/ajpendo.00600.2013` — `primary`
2. Exercise-Induced Catecholamines Activate the Hippo Tumor Suppressor Pathway to Reduce Risks of Breast Cancer Development (2017). DOI `10.1158/0008-5472.can-16-3125` — `primary`
3. Exercise Capacity and All-Cause Mortality in Male Veterans With Hypertension Aged ≥70 Years (2014). DOI `10.1161/hypertensionaha.114.03510` — `primary`
4. Effect of Exercise or Metformin on Biomarkers of Inflammation in Breast and Colorectal Cancer: A Randomized Trial (2020). DOI `10.1158/1940-6207.capr-20-0188` — `primary`
5. Effects of Dietary Weight Loss and Exercise on Insulin-Like Growth Factor-I and Insulin-Like Growth Factor-Binding Protein-3 in Postmenopausal Women: A Randomized Controlled Trial (2013). DOI `10.1158/1055-9965.epi-13-0337` — `primary`
6. Blood pressure and calf muscle oxygen extraction during plantar flexion exercise in peripheral artery disease (2017). DOI `10.1152/japplphysiol.01110.2016` — `primary`
7. Dietary Weight Loss and Exercise Effects on Serum Biomarkers of Angiogenesis in Overweight Postmenopausal Women: A Randomized Controlled Trial (2016). DOI `10.1158/0008-5472.can-16-0399` — `primary`
8. Abnormal protein turnover and anabolic resistance to exercise in sarcopenic obesity (2013). DOI `10.1096/fj.12-224006` — `primary`
9. Changes in Dietary Inflammatory Index Patterns with Weight Loss in Women: A Randomized Controlled Trial (2020). DOI `10.1158/1940-6207.capr-20-0181` — `primary`
10. Nitric oxide and voluntary exercise together promote quadriceps hypertrophy and increase vascular density in female 18-mo-old mice (2012). DOI `10.1152/ajpcell.00305.2011` — `primary`
11. Exercise training undertaken by people within 12 months of lung resection for non-small cell lung cancer (2019). DOI `10.1002/14651858.cd009955.pub3` — `primary`
12. Aerobic Exercise Attenuates Frailty in Aging Male and Female C57Bl/6 Mice and Effects Systemic Cytokines Differentially by Sex (2021). DOI `10.1093/gerona/glab297` — `primary`

## What this changes

Do not treat exercise as one generic anti-aging lever in review or trial design. Split claims by endpoint family before making a broad conclusion: inflammation, tumor biology, vascular oxygenation, muscle synthesis, mortality/exercise capacity, and diet-linked biomarker changes are different evidence lanes.

## Limitations

- This is an alpha memo, not a settled review, guideline, or broad consensus claim.
- Only 10 references in the 12-source bundle have A/B-bound receipts in this run; two source-bundle entries are corpus-context references for breadth and should not be used as direct proof.
- The topic is heterogeneous, so the memo should guide subtopic extraction rather than support one pooled treatment-effect claim.
- Animal, mechanistic, and human endpoints are deliberately separated; cross-lane analogies remain hypotheses.

## Strongest counter-evidence

- No A_core/B_context counter-evidence was classified in this run, but the heterogeneity of endpoints is itself a constraint on broad claims.
- If independent receipt expansion shows the same endpoint families behave uniformly across populations and models, this context-specific framing weakens.

## Next extraction

- Split exercise into endpoint-specific child topics: inflammatory-axis response, cancer/tumor biology, vascular oxygenation, muscle synthesis/anabolic resistance, fracture/bone outcomes, and mortality/exercise capacity.
- For each child topic, require at least two independent A/B-bound source papers before publishing a broad claim.
- Re-run counter-evidence search against each child topic so “no counter-evidence found” is not confused with proof of absence.

## Provenance / priority

- **Topic:** `exercise`
- **Author:** Dom Lynch
- **Version:** 1.0
- **License:** CC BY-NC 4.0
- **Suggested citation:** Dom Lynch. (2026). Exercise signals are endpoint-specific, not uniformly generalizable. ReseaRka Evidence Index. Version 1.0.
- **Run:** `exercise-evidence-2026-05-16T18-12-38Z`


Exercise signals are endpoint-specific, not uniformly generalizable

A source-grounded submission for Researka review. Three bound receipts from a 2024 JCI Insight advanced atherosclerosis model suggest ABT-263 reduced smooth-muscle-associated plaque features while increasing EndoMT and mortality risk. The claim is intentionally narrow and preclinical.

sha256:33d1652f5398799e785088748e00954882d7c9ef491cec9feb193cbd83e3ccef

## Research Question

In advanced atherosclerotic Apoe-/- mouse models, does ABT-263 senolytic treatment support a narrow warning that senescent-cell clearance can reduce smooth-muscle-associated plaque features while simultaneously increasing endothelial-to-mesenchymal transition and mortality risk, and should this signal be framed as a therapeutic-window concern rather than as evidence that senolytics are broadly harmful or broadly beneficial?

## Search Summary

This submission uses the retained Researka v4 senolytic evidence run from 2026-05-17. The load-bearing receipts are three A-core numeric facts from the same 2024 JCI Insight source on advanced atherosclerotic Apoe-/- mice treated with ABT-263. Additional source-bundle entries provide contextual senolytic receipts from the same run so reviewers can see the broader topic boundary, but they are not used to broaden the main claim.

## Evidence Landscape

The central evidence is source-concentrated and preclinical. That is acceptable only for a frontier warning memo because the signal is counter-consensus and internally coherent: the same model/source reports plaque-cell reduction, EndoMT increase, and mortality risk. Contextual bundle papers cover adjacent senolytic biology, but the thesis should remain limited to advanced plaque biology and ABT-263 rather than general anti-aging use.

## Key Findings

Load-bearing evidence receipts:
- fact_id=12623: reduced SMC by 90% in advanced atherosclerotic Apoe-/- mice fed western diet; intervention: ABT-263 at 100 mg/kg or 50 mg/kg; source DOI: 10.1172/jci.insight.173863
- fact_id=12624: increased EC contributions to lesions via EC-to-mesenchymal transition (EndoMT) by 60% in advanced atherosclerotic Apoe-/- mice fed western diet; intervention: ABT-263 at 100 mg/kg or 50 mg/kg; source DOI: 10.1172/jci.insight.173863
- fact_id=12622: was associated with a > 50% mortality rate in advanced atherosclerotic Apoe-/- mice fed western diet; intervention: ABT-263 at 100 mg/kg or 50 mg/kg; source DOI: 10.1172/jci.insight.173863

Taken together, these receipts support a narrow interpretation: ABT-263 may clear or reduce plaque-associated smooth muscle cells while worsening features linked to plaque instability and survival. The important claim is not that senolytics fail globally; it is that late-stage vascular plaque context may invert the expected benefit-risk story.

## Limitations

The main limitation is single-source concentration: all three load-bearing receipts come from one 2024 JCI Insight paper. The model is advanced atherosclerotic Apoe-/- mice, not humans, and mortality may reflect dose, off-target toxicity, disease stage, or ABT-263-specific biology. The source bundle is therefore sufficient for a cautious alpha memo, but not for clinical guidance or a broad senolytic class claim.

## Gaps Identified

Useful falsification work includes independent replication in advanced plaque models, dose-response separation of smooth-muscle-cell loss from EndoMT induction, comparison with non-ABT-263 senolytics, and human vascular safety evidence. A broader review should also test whether earlier-stage plaque, lower-dose exposure, or intermittent treatment changes the direction of the risk signal.

## Conclusion

The current evidence supports submitting a cautious Researka alpha memo: senolytic ABT-263 may backfire in advanced plaques by coupling plaque-cell reduction with EndoMT and mortality risk. The conclusion should be published only as a bounded frontier signal with explicit single-source and preclinical caveats, not as settled evidence against senolytic therapy.


RESEARKA

Alpha Memos